Chemotherapy-Induced Hypersensitivity Reactions

Gobel, Barbara Holmes

doi:10.1188/05.onf.1027-1035

Cited by 21 publications

(4 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Predictors of IRR risk of other mAbs include age, race, sex, geographic location, malignancy, and previous chemotherapy administration. 31 The sex assigned at birth for most participants was male in 704/085 and female in 703/081; higher incidence of hypersensitivity or other allergic reactions associated with mAb administration have been reported among women compared with men. 32 History of allergic disorder or atopy was significantly associated with IRR in 703/081, as has been reported for other mAbs.…”

Section: Discussionmentioning

confidence: 99%

Infusion Reactions After Receiving the Broadly Neutralizing Antibody VRC01 or Placebo to Reduce HIV-1 Acquisition: Results From the Phase 2b Antibody-Mediated Prevention Randomized Trials

Takuva

Karuna

Juraska

et al. 2022

JAIDS Journal of Acquired Immune Deficiency Syndromes

View full text Add to dashboard Cite

Background:The antibody-mediated prevention (AMP) studies (HVTN 703/HPTN 081 and HVTN 704/HPTN 085) are harmonized phase 2b trials to assess HIV prevention efficacy and safety of intravenous infusion of anti-gp120 broadly neutralizing antibody VRC01. Antibodies for other indications can elicit infusion-related reactions (IRRs), often requiring premedication and limiting their application. We report on AMP study IRRs.Methods: From 2016 to 2018, 2699 HIV-uninfected, at-risk men and transgender adults in the Americas and Switzerland (704/085) and 1924 at-risk heterosexual women in sub-Saharan Africa (703/ 081) were randomized 1:1:1 to VRC01 10 mg/kg, 30 mg/kg, or placebo. Participants received infusions every 8 weeks (n = 10/ participant) over 72 weeks, with 104 weeks of follow-up. Safety assessments were conducted before and after infusion and at noninfusion visits. A total of 40,674 infusions were administered.Results: Forty-seven participants (1.7%) experienced 49 IRRs in 704/ 085; 93 (4.8%) experienced 111 IRRs in 703/081 (P , 0.001). IRRs occurred more frequently in VRC01 than placebo recipients in 703/081 (P , 0.001). IRRs were associated with atopic history (P = 0.046) and with younger age (P = 0.023) in 703/081. Four clinical phenotypes of IRRs were observed: urticaria, dyspnea, dyspnea with rash, and "other." Urticaria was most prevalent, occurring in 25 (0.9%) participants in 704/ 085 and 41 (2.1%) participants in 703/081. Most IRRs occurred with the initial infusion and incidence diminished through the last infusion. All reactions were managed successfully without sequelae.Conclusions: IRRs in the AMP studies were uncommon, typically mild or moderate, successfully managed at the research clinic, and resolved without sequelae. Analysis is ongoing to explore potential IRR mechanisms.

show abstract

Section: Discussionmentioning

confidence: 99%

Infusion Reactions After Receiving the Broadly Neutralizing Antibody VRC01 or Placebo to Reduce HIV-1 Acquisition: Results From the Phase 2b Antibody-Mediated Prevention Randomized Trials

Takuva

Karuna

Juraska

et al. 2022

JAIDS Journal of Acquired Immune Deficiency Syndromes

View full text Add to dashboard Cite

show abstract

“…A Carboplatina representa o segundo quimioterápico associado à maior incidência de reações adversas imediatas à infusão neste estudo (20%). Pertencente à classe dos Agentes Alquilantes, é um quimioterápico análogo das platinas, utilizado para tratar uma ampla variedade de cânceres (Gobel, 2005).…”

Section: Incidência De Reações Adversas Imediatas à Infusão Relacionadas Aos Quimioterápicosunclassified

Perfil das reações adversas imediatas à infusão de quimioterapia em pacientes ambulatoriais em um Hospital Universitário fluminense

Borges¹,

Salles

Camuzi

2021

RSD

View full text Add to dashboard Cite

A maioria dos agentes antineoplásicos pode ocasionar reações infusionais, das quais a incidência e o perfil variam conforme as características de cada medicamento, podendo ou não ser imunomediadas. Com o objetivo descrever o perfil das reações adversas imediatas à infusão de quimioterapia em pacientes ambulatoriais, desenvolvemos este estudo exploratório, descritivo, transversal e retrospectivo, a partir registros das notificações das reações adversas realizados pela equipe multiprofissional de março/2018 a março/2019, e dos prontuários dos participantes. As reações adversas imediatas à infusão de quimioterapia foram classificadas quanto à gravidade, de acordo com a Common Terminology Criteria for Adverse Events, e quanto à causalidade usando algoritmo de Naranjo. De um total de 6.832 instalações endovenosas de quimioterapia realizadas no período de estudo, foram registradas 30 reações adversas imediatas, envolvendo 28 pacientes (83% mulheres), principalmente com Paclitaxel (44%) e Carboplatina (20%). Conforme Naranjo, 60% das reações infusionais foram classificadas como prováveis. O tempo médio para manifestação das reações foi de 40 minutos, sendo a mais rápida com Docetaxel (5 minutos), e a mais demorada com Paclitaxel (180 minutos). A gravidade das reações variou entre leve (64%) e moderada (30%). Os segmentos orgânicos mais comprometidos foram respiratório (27%) e cardiovascular (26%); e 83% dos sintomas apresentados estavam previstos nas bases de dados. Com este estudo, foi possível identificar as principais reações imediatas à infusão no grupo em estudo, bem como os quimioterápicos envolvidos com as mesmas, contribuindo para o manejo seguro dos pacientes e no controle eficaz das reações pela equipe multidisciplinar.

show abstract

“…Las reacciones de hipersensibilidad (RH) son definidas como respuestas impredecibles, que no pueden ser explicadas ni por la acción farmacológica ni por el perfil de toxicidad del medicamento, producidas por un mecanismo inmunológico, humoral o celular 1,2 . Casi todos los quimioterápicos tienen potencial para causar una RH, pero determinados grupos han sido asociados con un mayor riesgo, como los derivados del platino (cisplatino, carboplatino y oxaliplatino), los taxanos (paclitaxel y docetaxel), las asparraginasas, los anticuerpos monoclonales y las epipodofilotoxinas 3 .…”

Section: Reacciones De Hipersensibilidad a Antineoplásicosunclassified

Revisión de las reacciones de hipersensibilidad a antineoplásicos

Cortijo-Cascajares

Jiménez-Cerezo

Tejada

2012

Farmacia Hospitalaria

View full text Add to dashboard Cite

show abstract

Chemotherapy-Induced Hypersensitivity Reactions

Abstract: The potentially life-threatening nature of hypersensitivity reactions to chemotherapy requires that nurses have a plan to manage them. This may include a written policy on staff education and training, appropriate equipment, and medications.

Cited by 21 publications

References 40 publications

Infusion Reactions After Receiving the Broadly Neutralizing Antibody VRC01 or Placebo to Reduce HIV-1 Acquisition: Results From the Phase 2b Antibody-Mediated Prevention Randomized Trials

Infusion Reactions After Receiving the Broadly Neutralizing Antibody VRC01 or Placebo to Reduce HIV-1 Acquisition: Results From the Phase 2b Antibody-Mediated Prevention Randomized Trials

Perfil das reações adversas imediatas à infusão de quimioterapia em pacientes ambulatoriais em um Hospital Universitário fluminense

Revisión de las reacciones de hipersensibilidad a antineoplásicos

Contact Info

Product

Resources

About